Gene Therapy Company focuses on correcting or compensating for diseases caused by abnormal genes by introducing foreign normal genes into target cells.

This article summarized the latest R&D progress of Nitrazepam, the Mechanism of Action for Nitrazepam, and the drug target R&D trends for Nitrazepam.

Landmark Phase 3 MARIPOSA Study achieves its main goal, demonstrating clinically relevant enhancement for RYBREVANT® and Lazertinib when compared to Osimertinib in EGFR-Mut patients.

This article summarized the latest R&D progress of Nimesulide, the Mechanism of Action for Nimesulide, and the drug target R&D trends for Nimesulide.

Akt, also known as protein kinase B, is a crucial enzyme that plays a significant role in various cellular processes within the human body.

This article summarized the latest R&D progress of Natamycin, the Mechanism of Action for Natamycin, and the drug target R&D trends for Natamycin.

Gracell Biotechnologies has showcased updated long-term data from a continuing Phase 1 trial. This trial is assessing GC012F, a candidate for autologous CAR-T treatment that simultaneously targets CD19 and the B-cell maturation antigen (BCMA).

This article summarized the latest R&D progress of Moxidectine, the Mechanism of Action for Moxidectine, and the drug target R&D trends for Moxidectine.

Biosimilar drugs: These are therapeutic biological products that have similarity in quality, safety, and efficacy with a previously registered reference drug.

This article summarized the latest R&D progress of Lurbinectedin, the Mechanism of Action for Lurbinectedin, and the drug target R&D trends for Lurbinectedin.

Elicio Therapeutics has revealed encouraging initial data related to relapse-free survival from their ongoing Phase 1 investigation of their primary asset, ELI-002.

This article summarized the latest R&D progress of Lidocaine hydrochloride, the Mechanism of Action for Lidocaine hydrochloride, and the drug target R&D trends for Lidocaine hydrochloride.